Allergic asthma is an important public health problem and is a complicated respiratory sickness that is characterized by bronchial inflammation, bronchoconstriction, and breathlessness. Asthma is orchestrated by type 2 immune response and remodeling is one of the important outputted problem in chronic asthma. Thymol is a naturally occurring monocyclic phenolic, it has a series of biological properties, and its immunomodulatory and anti-remodeling effects on allergic asthma were evaluated. The OVA-LPS-induced asthmatic mice were treated with thymol. Methacholine challenge test, eosinophil count, and levels of IL-4, IL-5, IL-13, and IL-33 in bronchoalveolar lavage fluid, total and OVA-specific IgE levels in serum, remodeling factors, gene expression of TGF-β, Smad2, Smad3, and lung histopathology were done. Treatment with thymol could control AHR, eosinophil percentage levels of Th2 cytokines and Igs, remodeling factors, expression of TGF-β, Smad2 and Smad3 genes, inflammation, goblet cell hyperplasia, and mucus production in asthmatic mice. Thymol can control asthma pathogens and related remodeling and fibrosis bio-factors and can be a potential treatment of asthma.
Keyphrases
- lung function
- transforming growth factor
- chronic obstructive pulmonary disease
- allergic rhinitis
- epithelial mesenchymal transition
- public health
- gene expression
- immune response
- cystic fibrosis
- lps induced
- air pollution
- oxidative stress
- high fat diet induced
- signaling pathway
- poor prognosis
- mesenchymal stem cells
- climate change
- dendritic cells
- bone marrow
- type diabetes
- adipose tissue
- insulin resistance
- skeletal muscle
- long non coding rna
- gram negative
- liver fibrosis
- atopic dermatitis